Lang Huizhu

exchangealt 中文
  • Publish Date：2026-05-21
  • Update Date：2026-05-21
  • Units：Institute of Information Management
 
Photo of Lang Huizhu

Professor
Lang Huizhu

Office            Room 521, FL 5, Nursing Building
Contact         (02)2826-7015
Fax                (02)2823-7298
Email             hclang@nycu.edu.tw
 
 
Research Area
Cost Effectiveness Evaluation
Hospital performance management
 
Courses
Health Technology and Economic Assessment
Healthcare Operation Management
Medical Decision Making
 
 
 
  • Academic Background
    • Ph.D., Healthcare Management, The Johns Hopkins University
    • Master, Public Health, National Yang-Ming Medical College
    • Bachelor, Public Health, Chinese Medical University
  • Curriculum Vitae
  • Full-time Professor, Institute of Hospital and Health Care Administration, National Yang Ming Chiao Tung University
  • Associate Professor, Institute of Hospital and Health Care Administration, National Yang Ming University
  • Lecturer, Institute of Hospital and Health Care Administration, National Yang Ming University
 
  1. Lin WY1, Tan EC 2, Cheng E, Lang HC*. Real-World Cost-Effectiveness of Post-Acute Care or General Rehabilitation Care. MOST 105-2410-H-010 -012 -SS2.
  2. Tzeng YH, Yin WH, Lin KC, Wei J, Liou HR, Sung HJ, Lang HC. Factors Associated With the Utilization of Outpatient Virtual Clinics: Retrospective Observational Study Using Multilevel Analysis. J Med Internet Res. 2022 Jul 31. doi: 10.2196 /40288. Epub ahead of print. PMID: 35917486.
  3. Chiu CM, Lin CS, Chen MS, Lang HC*. Evaluating the Comparative Efficiency of Medical Centers in Taiwan: A Dynamic Data Envelopment Analysis Application. BMC Health Services Research. 2022; Apr 2;22(1):435. 19 Taiwan Financial structure and operational performance analysis of the medical center PI-Yadong Hospital Industry-Academic Cooperation
  4. Chiou LJ, Lang HC*. Potentially Preventable Hospital Readmissions after Patients' First Stroke in Taiwan. Submitted to Scientific Report. MOST 105-2410-H-010 -012 -SS2. Science Report 2022; Mar 8;12(1);3743 . doi: 10.1038/s41598-022-07791-3.
  5. Leung JH, Chang CW, Chan AL, Lang HC*. Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan. Future Oncol. 2022 Feb 2. doi: 10.2217/fon -2021-0785. Online ahead of print. Pharmaceutical Inspection Center
  6. Lin CS, Chiu CM, Huang YC, Lang HC*, Chen MS*. Evaluating the Operational Efficiency and Quality of Tertiary Hospitals in Taiwan: The Application of the EBITDA Indicator to the DEA Method and TOBIT Regression. Healthcare (Basel). 2021 Dec 29;10(1):58. doi: 10.3390/healthcare10010058. Analysis of the financial structure and operational performance of 19 medical centers in Taiwan PI-Yadong Hospital Industry-Academic Cooperation
  7. Lang Huizhu. The impact and reflection of the COVID-19 epidemic on the medical industry and public health. Humanities and Social Sciences Brief. Department of Humanities and Social Sciences Research Development of the Ministry of Science and Technology. 2021; 22(4): 31-37.
  8. Leung JH, Lang HC, Wang SY, Lo HF, Chan AL. Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer. Expert Rev Pharmacoecon Outcomes Res. 2022 Apr; 22(3): 489-496. doi: 10.1080/14737167.2021.1954506. The impact of including new cancer drugs in national health insurance PI MOST 107-2410-H-010-011
  9. Leung WC, Lang HC, Wang SY, Leung H, Chan LF. Cost‐utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck. Expert Review of Pharmacoeconomics & Outcomes Research. 2021Jun;21( 3):489-495. doi: 10.1080/14737167.2021.1890585. Epub 2021 Mar 17. The impact of the inclusion of new cancer drugs in national health insurance PI MOST 107-2410-H-010-011
  10. Yang CP, Li CY, Huang WJ, Yu HL, Yang CC, Lu MC, Lang HC*, Yan YH*. Short-, mid- and long-term associations between PM2.5 and stroke incidence in Taiwan. J Occup Environ Med 2021 Sep 1;63(9):742-751. Cost-effectiveness analysis of risk adjustment using health insurance database: taking stroke treatment as an example MOST 105-2410-H-010 -012 -SS2
  1. Chiu CM, Huang Y, Chen MS, Lin CS, Lang HC*. The Efficiency Analysis of 19 Medical Centers in Taiwan, was accepted to ISPOR Asia Pacific 2020. ISPOR Asia Pacific 2020. Virtual conference
  2. Lang HC, Tan ECH, Lin WY, Chang CW. Real-World Cost and Effectiveness Analysis Of Post-Acute Care Vs. Non-Pac for Stroke Patients after Discharge from Hospital. ISPOR 2019 Europe 2-6 November 2019, Copenhagen, Denmark.
  3. Chang CW (張智雯). Cost-effectiveness of the Second Line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC). ISPOR 2019. 18-22 May 2019. New Orleans, LA, USA.
  4. Kuo WJ(郭琬蓉), Lang HC, Lin CL. Budget Impact Analysis of Novel Direct-Acting Antivirals for Chronic Hepatitis C Virus Infection in Taiwan. ISPOR 2019. 18-22 May 2019. New Orleans, LA, USA.
  5. Lang HC, Tan ECH, Yang CK, Chang CW, Yang MH. Cost-effectiveness of immunotherapy strategies for advanced melanoma in Taiwan. ISPOR Asia Pacific 2018. 8-11 September 2018, Tokyo, Japan.
  6. Lang HC, Lin WC, Niu DM. Economic Evaluation of Neonatal Screening for Congenital Hypothyroidism. ISPOR 20th Annual European Congress4-8 November 2017, Glasgow, Scotland
  7. Lin YL, Lang HC*. Cost-Effectiveness Analysis of Laparoscopic Surgery for Presumed Leiomyomas.ISPOR 19th Annual European Congress. 29 Oct.-2 Nov. 2016, Vienna, Austria
  8. Chen RCY, Lang HC, Chuang SY, Cheng HM. Application Of Risk Adjusted Cost-Effectiveness Analyses For Stroke Treatment. ISPOR 19th Annual European Congress. 29 Oct.-2 Nov. 2016, Vienna, Austria
  9. Lang HC, Cheng E. The Relationship between Economic Business Cycle and Health Care Utilization. iHEA Italy, Milan July 13-15, 2015
  10. Wang YP, Lang HC, Lu CL. Use of ursodeoxycholic acid and the risk of colorectal cancer: a nationwide, population based, case-control database study
Back